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Objectives: The aim of the research is to explore the main determinants driving 
the diffusion of new medical technologies. MethOds: We investigated the diffu-
sion two medical technologies: cardiac ablation for atrial fibrillation (CA-AF) and 
left atriage appendage closure (LAAC). Our sample consists of all Italian hospitals 
that adopted the two focal technologies in the period 2009-2012. We classified 
the hospitals according to ownership, type, teaching status and urban location. 
In the first regression we investigate the diffusion, i.e. yearly number of proce-
dures performed by each hospital, in the second one the average frequency of use, 
measured as the average number of days between two subsequent procedures 
in each hospital. Results: Different types of hospitals show different baseline 
trends of diffusion. Public hospitals, both teaching and non-teaching, use less 
CA-AF compared to private non-teaching ones. Among hospital-level variables, 
the use of DRG-based reimbursement has a positive effect on CA-AT diffusion, 
not significant for LAAC. The rank in adoption is an important factor only for 
CA-AF. The impact of the number of other hospitals contemporaneously adopting 
the technology is negative for both technologies, but significant only for CA-AF. 
The average time between two subsequent uses is negatively correlated with the 
diffusion for both technologies. Regional contextual variables, including type of 
funding and socio-economic variables do not show significant impacts, with the 
exception of per capita public health expenditure, that enhances the diffusion 
of both technologies, and the ratio between public health expenditure and GDP 
in the case of CA-AF. The average frequency of use decreases over time for both 
technologies. Neither hospital-level variables nor regional-level ones do not show 
significant effects. The only variable with a significant and negative impact on the 
frequency of use of CA-AF is the number of competitors. cOnclusiOns: These 
results are consistent with previous literature.
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Objectives: There is evidence that in Greece, economic crisis has substantially 
affected chronic patients’ access to health care services. The aim of the study was 
to depict the current situation and identify the challenges and opportunities regard-
ing the management of chronic diseases, in times of economic crisis and auster-
ity from the aspect of both providers and patients. MethOds: Representatives of 
chronic patients and medical associations were invited to participate in a focus 
group session. Four diseases (Type 2 Diabetes, Hypertension, COPD, and Alzheimer) 
were selected based on their epidemiology and socioeconomic impact on the Greek 
health care system. Fifteen representatives participated and their statements were 
recorded, analyzed and categorized into 4 categories. Results: Common issues in 
the management of chronic diseases under study appear to be the low quality of 
health services, fragmented primary care system and absence of specialized cent-
ers for the management of chronic diseases. These problems of the Greek health 
system were found to be magnified because of the recession. Furthermore, the 
increased numbers of unemployed, uninsured and patients at risk of poverty, puts 
additional pressure to the health system and futher undermines the quality of 
the health services. Economic and geographic barriers in access were reported, 
strengthening of the primary health system, development of patient registries, 
patient education regarding self-management and involvement of their associations 
in decision making was considered critical to the improvement of disease manage-
ment. cOnclusiOns: The management of chronic diseases was challenging even 
before the economic crisis in Greece, but the current economic framework poses 
additional threats for the health care system jeopardizing patients’ health and its 
sustainability due to an increased risk for future costs. Investment in patients and 
physicians education regarding chronic diseases management was thought to be 
the key for improving this situation.
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Objectives: Aim of the study was to investigate chronic patients’ out-of-pocket 
expenditures and the percent of the households subjected to catastrophic health 
expenditures (CHE) during the economic crisis. MethOds: A cross-sectional study 
was conducted among 1600 chronic patients suffering from diabetes, hyperten-
sion, COPD and Alzheimer. Patients were asked to indicate the amount they spent 
for primary and secondary health care services and for pharmaceuticals. Current 
household income and income decrease since 2010 were also measured. CHE was 
defined as any amount spent for health which accounts for more than 20% of the 
total household income. Results: 1594 patients responded to the survey (99.6%). 
In 2013, 7.8% of all households with at least one chronic condition patient were sub-
jected to CHE, compared to 3.6% in 2010. The analysis by disease showed that 11.4% 
in 2013 vs 6.2% in 2010 of the Alzheimer patients faced CHE, while the respective 
figures was 8.7% vs 2.9% for the COPD patients, 7.1% vs 3.4% for diabetic patients, 
and 4.2 vs 1.7% for the hypertensive patients. Pharmaceutical expenditures alone 
were deemed catastrophic for 4.6% of all the above patients in 2013 vs 1.6% before 
the introduction of the austerity measures and the health care reforms. Of the 
Alzheimer patients, 6.2% in 2013 vs 2.8% in 2010 faced CHE due to out-of-pocket 
payments for drugs, while the respective figures were found to be 3.4% vs 1.8% 
for the diabetic patients, 2.9% vs 0.9% for COPD patients and 1.7% vs 0.9% for the 
hypertensive patients. cOnclusiOns: After the introduction of austerity measures 
Apixaban (74.82±11.39 years) patients were older versus those who switched to dabi-
gatran (72.46±10.89 years, p< 0.0001) or rivaroxaban (73.50±11.27 years, p= 0.0193). 
Apixaban users (45.4%) were more female compared to dabigatran (38.4%, p= 0.0037) 
and rivaroxaban (40.4%, p= 0.0499). The mean CHADS2 score was higher for apixaban 
users (mean±SD 2.28±1.25) as compared to dabigatran (1.94±1.20, p< 0.0001) and 
rivaroxaban (2.18±1.25, p= NS) users. Apixaban patients had significantly higher 
baseline rates for congestive heart failure (p= 0.0111), hypertension (p= 0.0002), renal 
disease (p= 0.0017) and ischemic stroke/ transient ischemic attack (p= 0.0004) as 
compared to dabigatran users. Apixaban users (2.34±2.12) also had higher mean 
charlson comorbidity index scores as compared to dabigatran users (1.98±1.96, 
p= 0.0002). cOnclusiOns: Patients who switch to apixaban are older and sicker 
as compared to those switching to dabigatran or rivaroxaban. A detailed evaluation 
of patient characteristics on the treatment outcomes in NVAF patients switching 
from warfarin to NOAC is warranted in future.
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Objectives: To assess treatment patterns of lipid-lowering drugs in patients with 
hyperlipidemia or prior cardiovascular (CV) events (myocardial infarction, unsta-
ble angina, revascularization, ischemic stroke, transient ischemic attack or heart 
failure) who experience new CV events. MethOds: A retrospective population-
based cohort study was conducted using Swedish electronic medical records and 
national registers. Patients were included in the study based on a prescription of 
lipid-lowering treatment between January 1, 2006 and December 31, 2006 or history 
of CV events (prior to 2006) and followed until December 31,2012 for identification 
of new CV events and assessment of treatment patterns. Patients were stratified 
into three cohorts based on CV risk level. The index was the date of first new CV 
event during follow-up. All outcomes were assessed during the year following index 
date. Adherence was defined as medical possession ratio (MPR) > 0.80. Persistence 
was defined as no gaps > 60 days in supply of drug used at index date. Results: 
Of patients with CV event history (n= 6881), 49% were not on treatment at index. 
Corresponding data for CV risk equivalent and low/unknown CV risk patients were 
37% (n= 3226) and 38% (n= 2497), respectively. Mean MPR for patients on treatment at 
index was similar across cohorts (0.74–0.75). The proportions of adherent patients 
(60–63%) and persistent patients (56–57%) were also similar across cohorts. Dose 
escalation from the dose at index was seen within all cohorts, most notably for 
patients with low/unknown CV risk as 25% increased the dose after index. 2–3% of 
patients switched to a different drug after index while 5–6% of patients augmented 
treatment by adding another lipid-lowering drug. cOnclusiOns: Almost 50% of 
secondary prevention patients were not on any hyperlipidemia treatment, indi-
cating a potential therapeutic gap. Medication adherence and persistence among 
patients on hyperlipidemia treatment were suboptimal.
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Objectives: DIMATCH-HTA is a cohort study conducted to identify determi-
nants of blood pressure control among Portuguese-speaking African immigrants 
and Portuguese natives. The aim of this analysis is to study the determinants of 
health care utilization among hypertensive patients followed in Primary Health 
Care. MethOds: The sample comprises 1243 unbalanced observations from 513 
patients. Data were collected through questionnaires administered face-to-face 
at baseline, 6 and 12 months, and by telephone at 3 and 9 months after enrol-
ment. The variable used to capture health care utilization was the number of visits 
to the general practitioner related to hypertension, in the three months prior to 
each interview. The covariates were chosen based on Grossman’s health capital 
model of demand for health (1972) and Andersen conceptual model (1968). Amongst 
socioeconomic covariates, gender, age, ethnicity, education, monthly equivalent 
income, living alone and domestic work were considered. Health status was cap-
tured by the presence of diabetes, time since hypertension diagnosis and number 
of medicines. Self-perception of hypertension and private health insurance were 
also included. A GLMM model for count data, with a random effect on intercept 
was estimated. Model adequacy was checked via residual analysis and compari-
son of observed and predicted values. The analysis was performed in R (version 
3.0. 2) using lme4 package. Results: Results of estimated model indicated that 
total number of medicines (beta= 0.05, p-value= 0.03) and diabetes (beta= 0.40, 
p-value= 0.01) have significant positive impact on health care consumption. Patients 
whose occupation is domestic work have higher health care utilization (beta= 0.73, 
p-value= 0.02). On the other hand, those who self-assess their hypertension as con-
trolled (beta= -0.37, p-value= 0.02) and patients with higher income (in log scale, 
beta= -0.26, p-value= 0.01) have less visits to general practitioner related to hyper-
tension. cOnclusiOns: Based on the analysis it seems that not only variables 
related to health status, but also socioeconomic determinants impact health care 
utilization in hypertension.
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status. MethOds: New ischemic stroke (ICD-10 code I63) patients (no previous 
stroke within one year) between April 1, 2006 and March 31, 2009 (N= 4,350) were 
followed for one year using hospital Discharge Abstract Database. The severity of 
the stroke was obtained from the ambulatory care database. Median hospital costs 
by CMG+ group were obtained from Alberta Health. Hospitals were classified as 
teaching, community large, community medium, and community small hospitals. 
Hospitals were also classified as comprehensive stroke centre, urban and rural 
primary stroke centres, and other urban and rural hospitals. The adjusted risk 
factors in Bayesian Model included sex, age, all disease-specific co-morbidities, 
and disease severity. The results for four hospital types and five stroke center cat-
egories were calculated using the observed/expected approach. Results: The 30 
days mortality rates (95% CI) were lowest for teaching hospitals 10.1% (9.0%-11.2%) 
and large community hospitals (10.0%; 8.3%-11.8%), and the small community 
hospitals had the highest mortality rates (12.8%; 9.9%-15.8%). The mean LOS (95% 
CI) varied from 21.7 (20.9-22.6) days in teaching hospitals to 34.2 (28.6-41.0) days 
in community medium hospitals. The community medium hospitals had signifi-
cantly higher costs ($62,400; $49,900-$78,000) than the community large hospitals 
($32,900; $29,900-$36,200) and teaching hospitals ($37,000; $34,900-$39,200). Both 
comprehensive stroke and urban stroke centers had lower 30 day mortality rates 
(95% CI): 9.9% (8.8%-11.1%) and 9.7% (7.3%-12.0%); shorter LOS 21.6 (20.7-22.5) 
and 25.0 (22.7-27.6) days; and medium levels of costs $39,300 ($36,100-$40,700), 
compared to other hospitals. cOnclusiOns: The study shows the hospital type 
and stroke centre had limited effects on the mortality but significant impact on 
LOS and costs.
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Objectives: Stroke is the third leading cause of mortality worldwide, with sig-
nificant associated acute care hospitalization costs. The objective of this literature 
review was to delineate the costing methodologies employed for the estimation of 
in-patient hospital costs of stroke. MethOds: A PubMed search was performed 
using the keywords: hospitalization, cost analysis, acute stroke, and cost-effec-
tiveness; limited to publications in English from 2008 onwards. Inclusion criteria 
were patient-level data collection and detailed description of costing methodology 
applied. Cost-effectiveness and literature review studies were excluded. Results: 
In total 22 articles were included in the analysis. Cohort studies comprised 45% of 
the sample, followed by database analyses (32%), registered-based studies (9%), 
retrospective chart review studies (9%), and clinical trials (5%). Cost categories 
measured included direct medical costs (bed and staff, laboratory and imaging 
investigations, medications, rehabilitation and supportive nursing care), as well 
as indirect costs for the patients and their caregivers; in 2 studies the economic 
analysis was performed from a societal perspective. The resource utilization 
(excluding the database analyses) was identified in the medical records (80%), or 
from interviews (20%). Unit costs were primarily derived from national listings or 
hospital accounting files (36% each). The sample sizes (ranging from 100 to over 
60,000 patients), as well as the total costs (ranging from US$500 to US$150,000 per 
patient and from US$70 to US$13,000 per day) varied significantly, as a result of the 
heterogeneous cost variables described. cOnclusiOns: Methodologies differed 
in approach, complexity and specific cost variables evaluated. Consequently, the 
total costs varied significantly across studies which makes direct comparisons of 
outcomes difficult. A trend towards more sophisticated economic analyses, such 
as real costs measured versus hospital reimbursement rates, or hospitalization 
costs before versus after stroke, was observed. A more standardized approach to 
evaluating in-patient costs of stroke care is warranted.
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Objectives: Implantable loop recorders (ILR) are devices that continuously moni-
tor heart rhythm in patients with suspicion of cardiac arrhythmias. Reveal LinQ™ 
is a new insertable holter, an 87% smaller than Reveal® XT/DX that records abnor-
mal heart rhythm up to 3 years. The objective was to develop an economic tool 
which allows hospitals to quantify their cost savings from the simplified procedure 
of Reveal LinQ™. The tool was used to compare the costs of implanting Reveal® 
XT/DX in the cath lab to the costs of inserting Reveal LinQ™ out of the cath lab in 
three public hospitals of the Spanish National Health Care System. MethOds: A 
cost model was developed to assess the cost per procedure of Reveal LinQ™ and 
Reveal® XT/DX. The model included data of the personnel needed in the proce-
dure, the hospital setting, the hospitalization previous to the procedure, remote 
monitoring and post-procedure controls. Results: The total process-related 
savings of LinQ™ vs. Reveal® XT/DX in Virgen de la Salud, Puerta de Hierro and 
Virgen de la Arrixaca Hospitals were € 335 (13.3%), € 365 (13.1%) and € 517 (19.2%), 
respectively. Reveal LinQ™ was associated with a 66% reduction in cardiologist 
and OR-assistant time in Virgen de la Salud Hospital, a reduction of 15 minutes 
of cardiologist time in Puerta de Hierro Hospital and a reduction of 3 control vis-
its due to remote monitoring in Virgen de la Arrixaca Hospital. cOnclusiOns: 
The economic tool showed that the insertion of Reveal LinQ™ is associated 
with mean savings of € 406 from a hospital perspective compared to previous 
devices; mainly derived from moving the procedure out of the catheter lab, a 
reduction of the specialists’ time and in-hospital follow up visits due to remote 
monitoring.
in Greece a substantial increase of the households with at least one chronic condi-
tion patient which are subjected to CHE is recorded. There is a need for counter 
measures or/and an alternative policy context in order to reduce this catastrophic 
effect of economic crisis.
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Objectives: Through CYP2C19, the antiplatelet clopidogrel and the proton-pump 
inhibitor esomeprazole demonstrate a pharmacokinetic interaction that could 
translate into clinical inefficacy of clopidogrel. No medical consensus has been 
reached to date and therefore different guidelines are available. We aimed to 
evaluate the prescribing practices in the University Hospitals of Geneva (HUG) by 
measuring if the co-prescription was staggered as suggested by experts. We also 
measured the Omeprazole-CLopidogrel-Aspirin (OCLA) study impact on clopi-
dogrel use in our hospital. MethOds: Patient’s medical orders and nurse’s drug 
administration planning’s were analysed from January 2013 to April 2014 and the 
hospital pharmacy database from January 2000 to April 2014. To measure the “extra 
costs” of the implementation of different guidelines we built scenarios assum-
ing the clopidogrel or esomeprazole replacement with prasugrel or ticagrelor 
and pantozole or ranitidine, respectively. Results: Fifty seven percent of patients 
under clopidogrel had a co-prescription of esomeprazole during the study period. 
Among them 15% (154/1’000) had a medical order staggering the co-prescription 
(more than 10 hours apart), 16% a concomitant prescription and 64% no clear 
information. Five percent had 40 mg esomeprazole twice daily, hindering the 
possibility of staggering. Surprisingly we found a higher rate of patients hav-
ing a nurse’s schedule of more than 10 hours (39%, 417/1’071). Switching drugs 
would lead to increased costs for HUG of € 38’210 for prasugrel, € 34’800 for tica-
grelor, € 9’590 for pantoprazole and € 5’205 for ranitidine. A statistical significant 
decrease in trend of clopidogrel use was observed after the OCLA study publi-
cation. cOnclusiOns: The medical order’s information time frame should be 
mandatory in order to improve the transmission throughout the whole informa-
tion system and allow a clear staggering of clopidogrel-esomperazole co-prescrip-
tion avoiding drug-drug interactions when possible. Nurses take the initiative 
to stagger the co-prescription when these are not clearly defined by medical 
orders.
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Objectives: This study compares the outcome and health care performance 
among five health zones in Alberta by evaluating 30 days in-hospital mortality 
and length of stay (LOS) in patients with acute ischemic stroke, and total hospitali-
zation costs over one year. MethOds: Ischemic stroke (ICD-10 code I63) patients 
(without previous stroke within one year, N= 1,445) hospitalized between April 
1, 2007 and March 31, 2008 were followed for one year using hospital Discharge 
Abstract Database. The severity of the stroke was obtained from the ambulatory 
care database (NACRs). Median hospital costs by CMG+ group were obtained from 
Alberta Health. Logistic regression was used to analyse in-hospital mortality; nega-
tive binomial regression assessed LOS, and generalized gamma model (log link) 
for hospital costs. The risk-adjusted outputs were estimated adjusting for sex, 
all disease-specific co-morbidities, and stroke severity. We calculated observed/
expected results for five zones; South, Calgary, Central, Edmonton, and North 
Zones. Results: The risk-adjusted 30-days-mortality rates (95% CI) varied from 
7.8% (3.4%-12.1%) to 13.5% (9.6%-17.4%) in South and Central zones, respectively. 
The adjusted mean LOS varied from 16.3 (13.8-19.3) days in South Zone to 26.7 
(24.2-29.5) and 29.3 (24.0-35.8) days in Edmonton and North zones, respectively. The 
results show several statistically significant differences between the first episodes 
LOS between zones reflecting partly differences in the post-acute care in each loca-
tion for patients not discharged to home. The one-year-mean hospitalization costs 
varied from $72,300 ($55,000-$95,100) in North Zone to $25,500 ($20,500-$31,800) in 
South Zone. cOnclusiOns: The study shows significant variation in outcomes 
for ischemic stroke between the five health zones. Although the Provincial Stroke 
Strategy has largely standardized the stroke care between regions, differences in 
post-acute care arrangements have produced significant LOS and cost differences. 
More detailed analysis of the reasons for regional variation is needed for improve-
ment of the regional health care outcomes.
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Objectives: This study examines the association of 30 day in-hospital mortality, 
length of stay (LOS) during the first hospital episode, and hospitalization costs 
during one year after acute ischemic stroke by type of hospital and by stroke centre 
